Raising low levels of high-density lipoprotein cholesterol is an important target of therapy

American Journal of Cardiology

Volumn 85, Issue 5, 2000, Pages 645-650

  Boden, William E ^a   Pearson, Thomas A ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; EDITORIAL; HUMAN; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; RANDOMIZED CONTROLLED TRIALS; TRIGLYCERIDES;

EID: 0034154914     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00826-7     Document Type: Note

References (36)

1. Scandinavian Simvastation Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol, and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
4. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard, CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
6. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1616-1622.
7. Gofman JW, Lindgren F, Elliot H, Mantz W, Hewitt J, Strisower B, Herring V. The role of lipids and lipoproteins in atherosclerosis. Science 1950;111:166-171.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program. Summary of the Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
9. American College of Physicians. Guidelines for coronary serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels on screening tests for prevention of coronary heart disease in adults. Ann Intern Med 1996;124:515-517.
10. Second Joint Task Force of European, and Other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1999;1(suppl 5):53-58.
11. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714.
12. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-2838.
13. Rubins HB, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Mann D, Mayo-Smith M, Faas FH, Elam MB, Rutan GH, Anderson JW, Kashyap ML, Schectman G, for the Department of Veterans Affairs HDL Intervention Trial Study Group. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995;75:1196-1201.
14. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PWF, Salem DN, Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
15. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 1988:4(suppl):5A-10A.
16. Pearson TA, Buckley BH, Achuff SC, Kwiterovich PO, Gordis L. The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease. Am J Epidemiol 1979;109:285-295.
17. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Longterm predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol Circulation 1992;86:1165-1170.
18. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentration on coronary heart disease risk in the Helsinki Heart Study: implications of treatment. Circulation 1992;85:37-45.
19. Hill SA, McQueen MJ. Reverse cholesterol transport 190 a review of the process and its clinical implications. Clin Biochem 1997;30:517-525.
20. Hayek T, Oiknine J, Dankner G, Brook JG, Aviram M. HDL apolipoprotein A-I attenuates oxidative modification of low-density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 1995;721-725
21. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoproteins. FEBS Lett 1991;286:152-154.
22. Rubins HB. Current status of HDL intervention trials. Paper presented at: High-Density Lipoproteins and Coronary Heart Disease: A Symposium; November 7, 1998. Dallas, TX.
23. Rubins HB. Late-breaking clinical trials: Plenary session XII. Paper presented at: 71st Scientific Sessions of the American Heart Association; November 8-12, 1998; Dallas, TX.
24. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt T, Wittes J, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-418.
25. Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krause RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low-density lipoprotein particles. J Clin Invest 1993;92:141-146.
26. Superko HR. The atherogenic lipoprotein profile. Sci Med 1997;4:36-45.
27. Superko HR. Lipid disorders contributing to coronary heart disease: an update. Curr Probl Cardiol 1996;21:736-780.
28. Crouse JR III, Frohlich J, Ose L, Kush D, Wu M, Mercuri M. Effects of higher doses of simvastatin, and atorvastatin on high-density lipoprotein cholesterol, and apolipoprotein. Am J Cardiol 1999:1476-1477
29. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226:271-276.
30. Superko HR, Krause RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992;95:69-76.
31. Johansson JO, Egberg N, Asplund-Carlson A, Carlson LA. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridemic men. J Cardiovasc Risk 1997;4:165-171.
32. Morgan JM, Capuzzi DM, Guyton JR, Center RM, Goldberg R, Robbins DC, DiPette D, Jenkins S, Marcovina S. Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202.
33. Guyton JR. A comparative study of the effects of extended-release niacin and gemfibrozil on HDL levels in patients with low HDL cholesterol. Paper presented at: High-Density Lipoproteins and Coronary Heart Disease: A Symposium; November 7, 1988; Dallas, TX.
34. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-76.
35. Shah PK, Amin J. Low high-density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 1992;85:1279-1285.
36. Dzavik V, Teo K, Yokyama S, Modi R, Dinwoodie A, Burton JR, Tymchak WJ, Montague TJ. Effect of serum lipid concentration on restenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160 to 240 mg/dl and triglycerides <350 mg/dl. Am J Cardiol 1995;75:936-938.